Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
PALO ALTO, Calif., March 10, 2021 - Vincerx Pharma (Nasdaq: VINC) announced a poster presentation at the AACR Annual Meeting 2021, scheduled for April 10-15, 2021. The poster titled 'A novel small molecule drug conjugate' focuses on a new drug designed to treat multiple cancer types. The presentation will be led by Hans-Georg Lerchen as part of the Experimental and Molecular Therapeutics session. Vincerx, a clinical-stage life sciences company, aims to address unmet medical needs in oncology through innovative therapies.
- Poster presentation scheduled at a prominent oncology event.
- Focus on a novel therapeutic approach targeting multiple cancer types.
- The company has an exclusive license agreement with Bayer for its drug pipeline.
- None.
PALO ALTO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2021, being held virtually April 10-15, 2021.
| Poster presentation details: | |
| Poster Title: | A novel small molecule drug conjugate -αvβ3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types |
| Presenter: | Hans-Georg Lerchen |
| Session Type: | E-Poster Session |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | Novel Drug Delivery Systems |
| Permanent Abstract Number: | 1314 |
A copy of the presentation materials can be accessed on the Investors section of the Company’s website at www.vincerx.com once the presentation has concluded.
About Vincerx Pharma, Inc.
Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx’s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. For more information, please visit www.vincerx.com.
Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to: Vincerx’s business model, pipeline, strategy, timeline and product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.
Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of the COVID-19 pandemic; risks associated with preclinical or clinical development conducted prior to Vincerx’s in-licensing; failure to realize the anticipated benefits of the business combination with LifeSci Acquisition Corp.; failure to realize the benefits of Vincerx’s license agreement with Bayer; risks related to the rollout of Vincerx’s business and the timing of expected business milestones; changes in the assumptions underlying Vincerx’s expectations regarding its future business or business model; Vincerx’s ability to develop and commercialize product candidates; the availability and uses of capital; the effects of competition on Vincerx’s future business; and the risks and uncertainties set forth in the definitive proxy statement on Schedule 14A of LifeSci Acquisition Corp. filed with the SEC and reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the SEC from time to time by Vincerx. Forward -looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.
Contacts
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com
FAQ
What is the purpose of Vincerx Pharma's poster presentation at AACR 2021?
When will Vincerx Pharma's poster presentation take place?
Who is presenting Vincerx Pharma's poster at the AACR 2021?
What is the significance of the small molecule drug conjugate Vincerx is presenting?
